Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

811 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.
Sun J, Mao F, Liu C, Zhang F, Jiang D, Guo W, Huo L, Zhou L, Lau WY, Shi J, Cheng S. Sun J, et al. Among authors: lau wy. Signal Transduct Target Ther. 2023 Sep 27;8(1):368. doi: 10.1038/s41392-023-01604-3. Signal Transduct Target Ther. 2023. PMID: 37752117 Free PMC article. Clinical Trial.
Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis.
Zhang XP, Chai ZT, Gao YZ, Chen ZH, Wang K, Shi J, Guo WX, Zhou TF, Ding J, Cong WM, Xie D, Lau WY, Cheng SQ. Zhang XP, et al. Among authors: lau wy. HPB (Oxford). 2019 Dec;21(12):1687-1696. doi: 10.1016/j.hpb.2019.04.014. Epub 2019 May 29. HPB (Oxford). 2019. PMID: 31153833 Free article.
Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China.
Chen ZH, Zhang XP, Feng JK, Li LQ, Zhang F, Hu YR, Zhong CQ, Wang K, Chai ZT, Wei XB, Shi J, Guo WX, Wu MC, Lau WY, Cheng SQ. Chen ZH, et al. Among authors: lau wy. HPB (Oxford). 2022 Jul;24(7):1063-1073. doi: 10.1016/j.hpb.2021.11.016. Epub 2021 Dec 3. HPB (Oxford). 2022. PMID: 34961677 Free article.
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).
Yang Y, Sun J, Wu M, Lau WY, Zheng S, Wang XH, Chen X, Fan J, Dong J, Cai J, Chen M, Chen Y, Cheng Z, Dai C, Shan J, Du CY, Fang C, Hu H, Ji Z, Jia W, Li G, Li J, Li J, Liu C, Liu F, Ma Y, Mao Y, Niu Z, Shen J, Shi J, Shi X, Song W, Sun HC, Tan G, Tao R, Wang X, Wen T, Wu L, Xia J, Xiang BD, Yan M, Ying M, Zhang L, Zhang X, Zeng ZC, Zhang Y, Zhang Z, Zhou J, Zhou C, Zhou J, Zhou L, Zhou X, Zhu J, Zhu Z, Zhang Q, Li Q, Cheng S. Yang Y, et al. Among authors: lau wy. Liver Cancer. 2022 Jul 20;11(6):511-526. doi: 10.1159/000526038. eCollection 2022 Dec. Liver Cancer. 2022. PMID: 36589726 Free PMC article. Review.
Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.
Wang K, Xiang YJ, Yu HM, Cheng YQ, Liu ZH, Zhong JY, Feng S, Ni QZ, Zhu HF, Pan WW, Li JJ, Liang C, Zhou HK, Meng Y, Lau WY, Cheng SQ. Wang K, et al. Among authors: lau wy. Front Immunol. 2023 Feb 16;14:1107542. doi: 10.3389/fimmu.2023.1107542. eCollection 2023. Front Immunol. 2023. PMID: 36875125 Free PMC article.
811 results